A Phase II, Multi-center, Randomized, Double-blinded, Placebo-controlled Clinical Study Evaluating the Efficacy and Safety of TDI01 Suspension for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 07 Nov 2023
At a glance
- Drugs TDI 01 (Primary)
- Indications Pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Sinobiopharma
- 01 Nov 2023 Planned initiation date changed from 7 Nov 2023 to 2 Nov 2023.
- 30 Oct 2023 Planned initiation date changed from 18 Oct 2023 to 7 Nov 2023.
- 20 Oct 2023 Status changed from planning to not yet recruiting.